Targeting Transient Receptor Potential Melastatin‐2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer.

MLA

Chen, Zhen, et al. “Targeting Transient Receptor Potential Melastatin‐2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer.” Advanced Science, vol. 11, no. 35, Sept. 2024, pp. 1–17. EBSCOhost, https://doi.org/10.1002/advs.202310126.

APA

Chen, Z., Vallega, K. A., Boda, V. K., Quan, Z., Wang, D., Fan, S., Wang, Q., Ramalingam, S. S., Li, W., & Sun, S. (2024). Targeting Transient Receptor Potential Melastatin‐2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer. Advanced Science, 11(35), 1–17. https://doi.org/10.1002/advs.202310126

Chicago

Chen, Zhen, Karin A. Vallega, Vijay K. Boda, Zihan Quan, Dongsheng Wang, Songqing Fan, Qiming Wang, Suresh S. Ramalingam, Wei Li, and Shi‐Yong Sun. 2024. “Targeting Transient Receptor Potential Melastatin‐2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer.” Advanced Science 11 (35): 1–17. doi:10.1002/advs.202310126.